CymaBay Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced participation in three upcoming virtual investor conferences, aimed at addressing chronic liver diseases. The events include the SVB Leerink CybeRx Series "Liver Disease Day" on June 17, the Raymond James Human Health Innovation Conference on June 21, and the Piper Sandler "EASL Takeaway Day" on June 28. The company has received breakthrough therapy designation for its treatment, seladelpar, targeting primary biliary cholangitis.

NEWARK, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including SVB Leerink CybeRx Series: “Liver Disease Day” Conference taking place June 17, 2021, the Raymond James Human Health Innovation Conference taking place June 22, 2021 and the Piper Sandler “EASL Takeaway Day” taking place June 28, 2021.

SVB Leerink CybeRx Series: “Liver Disease Day” Conference
Date:	Thursday, June 17
Time:	1-on-1 meetings only
Raymond James Human Health Innovation Conference
Date:	Monday, June 21
Time:	9:20 am Eastern Time
	Panel Discussion: “Itching for New Therapies in Cholestatic Liver Disease”
Piper Sandler “EASL Takeaway Day”
Date:	Monday, June 28
Time:	3:00 pm Eastern Time / Fireside Chat
Webcast:	http://ir.cymabay.com/events

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin.

Cautionary Statements

Any statements made in this press release and at the investor conferences referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, its current and future clinical trials and CymaBay’s ability to fund current and planned clinical trials are forward looking statements that are subject to risks and uncertainties. Actual results and the timing of events regarding the further development of seladelpar could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of CymaBay's product development activities, including clinical trials; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of CymaBay's product candidates in the United States or worldwide; and the ability of CymaBay to obtain sufficient financing to complete development, regulatory approval and commercialization of its product candidates in the United States and worldwide. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.

For additional information about CymaBay visit www.cymabay.com.

Public Relations Contact:

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

FAQ

When is CymaBay participating in the SVB Leerink CybeRx Series conference?

CymaBay will participate in the SVB Leerink CybeRx Series conference on June 17, 2021.

What topics will be discussed at the Raymond James Human Health Innovation Conference?

At the Raymond James Human Health Innovation Conference on June 21, 2021, a panel discussion titled "Itching for New Therapies in Cholestatic Liver Disease" will take place.

What is the date and time for the Piper Sandler EASL Takeaway Day?

The Piper Sandler "EASL Takeaway Day" is scheduled for June 28, 2021, at 3:00 PM Eastern Time.

What is seladelpar and its significance for CymaBay?

Seladelpar is a first-in-class treatment for primary biliary cholangitis that has received breakthrough therapy designation from the FDA.

What can investors expect from CymaBay's participation in these conferences?

Investors can expect insights into CymaBay's clinical developments and updates on their pipeline for liver therapies during these conferences.